3K3A-APC is under clinical development by ZZ Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect 3K3A-APC’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 29 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 29 Sep 2022 increased 3K3A-APC’s Phase Transition Success Rate (PTSR) for Nerve Injury.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their 3K3A-APC Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

3K3A-APC overview

3K3A-APC is under development for the treatment of Alzheimer’s disease, acute ischemic stroke, amyotrophic lateral sclerosis (ALS), neurotrauma, diabetic foot ulcers, chronic wounds and sepsis. The drug candidate is administered through intravenous route. It is a recombinant genetically engineered variant of the naturally occurring activated protein C (APC). It was also under development for the treatment of septic shock.

ZZ Biotech overview

ZZ Biotech is a pharmaceutical and healthcare company focused on the development of biologic treatments for ischemic stroke and other neurological diseases. The company’s lead product includes 3K3A-APC, a genetically engineered recombinant human activated protein C (APC) that reduces anticoagulant activity, which minimizes the risk of bleeding and also maintains cell-protective. In addition, it is also used as anti-inflammatory activities indicated for the treatment acute ischemic stroke and diabetic foot ulcers. The company has operations in Sydney, Australia. ZZ Biotech is headquartered in Houston, Texas, the US.

Quick View 3K3A-APC LOA Data

Report Segments
  • Innovator
Drug Name
  • 3K3A-APC
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Infectious Disease
  • Metabolic Disorders
Key Developers
  • Sponsor Company: ZZ Biotech
  • Originator: Scripps Research Institute and University of Southern California
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.